Lombard Medical Technologies Share Discussion Threads

[rayrac] 19/10/2012 08:22

So far I'm in excellent health Stable thank you and I hope the same applies for you?

[stable] 18/10/2012 19:56

Rayrac.It is a long time since I have seen the name, I do hope you are keeping well.

[philo124] 18/10/2012 19:54

Ray, i saw the news but was concerned about the dilution on approval so didn't top up; the dilution is based on the share price the day before the approval. lol.
Canaccord had a 332p valuation last time i looked.

[rayrac] 18/10/2012 18:10

I bought back in today, had them on watch for ages, should have moved on the rns!

With a Market cap of less than £30m and a sure fire candidate for a t/o from the big boys across the pond. Seems we can't lose. A no brainer.

[philo124] 18/10/2012 10:08

Pretty Good move on £30k of trades.

[shorewalk] 18/10/2012 08:35

had this but took money when delisted - just bought back in as have always believed the technology. Here's hoping this time all goes according to plan.

[joeblogg2] 18/10/2012 08:25

Looking a bit perkier again, still well down in old money approx 0.7p

[philo124] 15/10/2012 19:06

If you have time, have a look at the RNS dated 20/04/2011; i would be interested
in your views of it.

[philo124] 15/10/2012 12:33

Yes, saw the RN but decided not to top up.

[skinny] 15/10/2012 10:56

London, UK, 15 October 2012 - Lombard Medical Technologies PLC (AIM:LMT), the specialist medical technology company focussed on innovative vascular products, today announces that it has received written feedback from the U.S. Food and Drug Administration ("FDA") on the pre-market approval ("PMA") application for AorfixTM, the Company's flexible stent graft for the endovascular repair of abdominal aortic aneurysms ("AAAs"). The FDA has provided the Company with a short list of questions. The Company believes these questions to be relatively straightforward and intends to submit answers to the Agency within 2 weeks. In addition the FDA has also scheduled a Good Manufacturing Process (GMP) audit of the Company's UK facility in late October. Such audits are typically part of the final stage of the FDA's review process.

[philo124] 06/10/2012 08:48

Certainly has been a big wait.

[seangwhite] 06/10/2012 00:42

FDA approval seems to be an elusive goal.
We test new lows if not done soon.

[jotoha2] 30/8/2012 08:09

And of course if there is another delay , as has been the case for the last 5 years , then the share price is likely to be 20p , no point in chasing this donkey for the time being .

[philo124] 30/8/2012 08:04

Canaccord note this am- 332p target based on US approval.

[skinny] 30/8/2012 07:09

Operational highlights

· Demand for Aorfix™ increased 23% in the four main EU markets (UK, Germany, Italy and Spain) with 195 patients treated (H1 2011: 158 patients)

· Total revenues increased 9% to £2.0m (H1 2011: £1.8m)

· Aorfix™ sales increased 11% in the four main EU markets to £1.0m (H1 2011: £0.9m)

o 53% growth in Germany reflecting expansion of direct sales team

· US regulatory approval submission on track; response to FDA including additional data analyses submitted in July 2012

· High angle clinical data from US PYTHAGORAS trial presented in June 2012

o Strong data despite extremely challenging patient group with high neck angles

· Launch of AorflexTM delivery system in April

o Encouraging clinician feedback from initial procedures

· Key hire - appointment of Ian Ardill to the Board as Chief Financial Officer in January 2012

o Significant financial, medical device, business development and international experience

Financial highlights

· Total commercial revenues increased 15% to £2.0m (H1 2011: £1.7m)

· £3.0m raised from issue of convertible loan notes to Invesco in March 2012

· Operating loss reduced by £0.6m to £4.4m (H1 2011: £5.0m)

· Loss after taxation for the period steady at £4.4m (H1 2011: £4.4m)

· Cash of £5.2m as at 30 June 2012 (30 June 2011: £12.1m)

[philo124] 29/8/2012 10:47

Today's "Sells" are actually Buys, one of them is mine; results tomorrow.

[skinny] 02/5/2012 07:09

Lombard Medical Technologies PLC
("Lombard Medical" or "Company")

Regulatory Update

London, UK, 2 May 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, announces that it has received feedback from the U.S. Food and Drug Administration ("FDA") as a result of its 100 day review. This review is part of the process for the pre-market approval ("PMA") application for AorfixTM, the Company's flexible stent graft for the endovascular repair of abdominal aortic aneurysms ("AAAs"). As previously announced the PMA filing was accepted for review in January 2012.

As part of this review process the FDA has requested some additional analyses of the existing clinical data set. The Company is confident that it can provide such analyses to satisfy the FDA's request, without the need for further patient enrolment into the trial, and now anticipates FDA approval in the fourth quarter of 2012.

As noted in the Company's announcement on 9th March 2012, the approval process with a regulatory authority such as the FDA can be subject to delays beyond the control of the Company. To this end, the Company strengthened its working capital position to ensure financing would be available into 2013 should there be such a delay in FDA approval beyond the third quarter of 2012 through the issuance of £3m of convertible loan notes (CLNs). These proceeds, together with the Company's existing cash resources, will be applied towards general working capital purposes; to ensure that the Company continues operating at current levels and preparations for the US launch of Aorfix™ remain on track.

CEO of Lombard Medical Technologies, Simon Hubbert, commented:
"We are encouraged by the progress made to date towards US approval of Aorfix™. The questions now raised by the FDA look to be readily addressable and we are confident that we remain on track to receive US approval later this year."

- Ends -

[backmarker] 01/5/2012 09:12

is this still on Bulford's list or did he manage to get everyone out above 200p ?

[skinny] 28/3/2012 09:19

RNS Number : 2422A

Lombard Medical Technologies PLC

28 March 2012

Lombard Medical Technologies PLC

Share Consolidation

London, UK, 28 March 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, is pleased to announce that the consolidation of the Company's ordinary share capital on the basis of 1 New Ordinary Share of 20 pence for every 200 Existing Ordinary Shares of 0.1 pence each has become effective following admission of the New Ordinary Shares to trading on AIM at 8.00 a.m. this morning.

As a result, the Company now has in issue 20,161,812 New Ordinary Shares of 20 pence each. The Company's new SEDOL code is B7FT8W8 and its new ISIN code is GB00B7FT8W85.

Capitalised terms used (but not defined) in this announcement have the same meanings as in the circular of the Company sent to shareholders on 9 March 2012 unless the context requires otherwise.

[philo124] 25/3/2012 20:55

Results this week.